102503-23-1

Basic information

• Product Name: N-(2,4-DIMETHOXYBENZYL)-N-METHYLAMINE
• Synonyms: N-(2,4-DIMETHOXYBENZYL)-N-METHYLAMINE;AKOS BC-0898;-(2,4-DIMETHOXYBENZYL)-N-METHYLAMINE;(2,4-diMethoxyphenyl)-N-MethylMethanaMiniuM;(2,4-DiMethoxybenzyl)MethylaMine;1-(2,4-DiMethoxyphenyl)-N-MethylMethanaMine;N-Methyl-2,4-Dimethoxybenzylamine;1-(2,4-Dimethoxyphenyl)
• CAS NO: 102503-23-1
• Molecular Formula: C₁₀H₁₅NO₂
• Molecular Weight: 181.23
• Mol File: 102503-23-1.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 262.1 °C at 760 mmHg
• Flash Point: 104.6 °C
• Appearance: /
• Density: 1.012 g/cm³
• Vapor Pressure: 0.0111mmHg at 25°C
• Refractive Index: 1.5
• Storage Temp.: 2-8°C(protect from light)
• PKA: 9.32±0.10(Predicted)
• CAS DataBase Reference: N-(2,4-DIMETHOXYBENZYL)-N-METHYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2,4-DIMETHOXYBENZYL)-N-METHYLAMINE(102503-23-1)
• EPA Substance Registry System: N-(2,4-DIMETHOXYBENZYL)-N-METHYLAMINE(102503-23-1)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 102503-23-1(Hazardous Substances Data)

Usage

General Description

N-(2,4-dimethoxybenzyl)-N-methylamine is a chemical compound with the molecular formula C10H15NO2. It is an organic amine compound, which means it contains nitrogen and is derived from ammonia. This chemical is used in the pharmaceutical industry, specifically as an intermediate in the synthesis of organic compounds and pharmaceutical drugs. It can also be used as a reagent in chemical processes such as the formation of amide bonds and the creation of heterocycles. N-(2,4-dimethoxybenzyl)-N-methylamine is a versatile compound with various applications in the field of organic chemistry.

InChI:InChI=1/C10H15NO2/c1-11-7-8-4-5-9(12-2)6-10(8)13-3/h4-6,11H,7H2,1-3H3

Upstream product

• 84572-02-1 N-(2,4-dimethoxybenzyl)formamide 
• 613-45-6 2,4-Dimethoxybenzaldehyde 
• 74-89-5 methylamine 
• 30354-18-8 N,N-dimethyl(methylene)ammonium chloride 
• 151-10-0 1,3-Dimethoxybenzene 

Downstream Products

• 1055306-73-4 1-(2,4-dimethoxyphenyl)-N-({4-fluoro-5-[2-(trifluoromethyl)pyridin-3-yl]-1H-pyrrol-3-yl}methyl)-N-methylmethanamine 
• 1055306-74-5 1-[5-(2-chloropyridin-3-yl)-4-fluoro-1H-pyrrol-3-yl]-N-(2,4-dimethoxybenzyl)-N-methylmethanamine 
• 1104806-90-7 4-[(2,4-dimethoxy-benzyl)-methyl-amino]-2-fluoro-N-thiazol-2-yl-benzenesulfonamide 
• 1120312-66-4 C₁₆H₁₈N₂O₄S 
• 1400942-56-4 4-bromophenyl 2,4-dimethoxybenzyl(methyl)sulfamate 
• 1400942-60-0 [1,1'-biphenyl]-4-yl benzyl(2,4-dimethoxybenzyl)sulfamate 
• 1055306-76-7 1-(2,4-dimethoxyphenyl)-N-{[4-fluoro-5-(2-fluoropyridin-3-yl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]methyl}-N-methylmethanamine 
• 1055306-77-8 1-(2,4-dimethoxyphenyl)-N-{[4-fluoro-5-(2-fluoropyridin-3-yl)-1-(phenylsulfonyl)-1H-pyrrol-3-yl]methyl}-N-methylmethanamine 
• 1055306-78-9 1-(2,4-dimethoxyphenyl)-N-({4-fluoro-1-(phenylsulfonyl)-5-[2-(trifluoromethyl)pyridin-3-yl]-1H-pyrrol-3-yl}methyl)-N-methylmethanamine 

Relevant articles and documents

Synthetic studies to help elucidate the metabolism of the preclinical candidate TBAJ-876—a less toxic and more potent analogue of bedaquiline

Bedaquiline is a novel drug approved in 2012 by the FDA for treatment of drug-resistant tuberculosis (TB). Although it shows high efficacy towards drug-resistant forms of TB, its use has been limited by the potential for significant side effects. In particular, bedaquiline is a very lipophilic compound with an associated long terminal half-life and shows potent inhibition of the cardiac potassium hERG channel, resulting in QTc interval prolongation in humans that may result in cardiac arrhythmia. To address these issues, we carried out a drug discovery programme to develop an improved second generation analogue of bedaquiline. From this medicinal chemistry program, a candidate (TBAJ-876) has been selected to undergo further preclinical evaluation. During this evaluation, three major metabolites arising from TBAJ-876 were observed in several preclinical animal models. We report here our synthetic efforts to unequivocally structurally characterize these three metabolites through their independent directed synthesis.

METALLOENZYME INHIBITOR COMPOUNDS

Provided are compounds having HDAC6 modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by HDAC6.

Synthesis of 2-amino-5-benzoyl-4-(2-furyl)thiazoles as adenosine A2A receptor antagonists

The discovery and synthesis of a series of 2-amino-5-benzoyl-4-(2-furyl)thiazoles as adenosine A2A receptor antagonists from a small-molecule combinatorial library using a high-throughput radioligand-binding assay is described. Antagonists were